Ariel Caviedes

Ariel Caviedes

Auto-generated profile, based on publicly available information

Ariel Caviedes

Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibañez, Santiago Chile

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Neuroscience
Verified
Journal Article
Closed access
MLM.A. Lopez-Verrilli
M.A. Lopez-Verrilli
ACA. Caviedes
A. Caviedes
ACA. Cabrera
A. Cabrera
SSS. Sandoval
S. Sandoval
UWUrsula Wyneken
Ursula Wyneken
MKMaroun Khoury
Maroun Khoury

14 November 2023 in Brain Research
Verified
Journal Article
Closed access
AFAnllely Fernandez
Anllely Fernandez
KCKatherine Corvalan
Katherine Corvalan
OSOctavia Santis
Octavia Santis
MMMaxs Mendez-Ruette
Maxs Mendez-Ruette
ACAriel Caviedes
Ariel Caviedes
UWUrsula Wyneken
Ursula Wyneken

4 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAriel Caviedes
Ariel Caviedes
BMBarbara Maturana
Barbara Maturana
KCKatherina Corvalán
Katherina Corvalán
AEAlexander Engler
Alexander Engler
FGFelipe Gordillo
Felipe Gordillo
UWUrsula Wyneken
Ursula Wyneken
Cell death by glutamate excitotoxicity, mediated by N-methyl-D-aspartate (NMDA) receptors, negatively impacts brain function, including but not limited to hippocampal neurons. The NF-κB transcription factor (composed mainly of p65/p50 subunits) contributes to neuronal death in excitotoxicity, while its inhibition should improve cell survival. Using the biotin switch method, subcellular fractionation, immunofluorescence and luciferase reporter assays, we found that NMDA stimulated NF-κB activity selectively in hippocampal neurons, while endothelial nitric oxide synthase (eNOS), an enzyme expressed in neurons, is involved in the S-nitrosylation of p65 and consequent NF-κB inhibition in cerebrocortical, i.e., resistant neurons. The S-nitro proteomes of cortical and hippocampal neurons revealed that different biological processes are regulated by S-nitrosylation in susceptible and resistant neurons, bringing to light that protein S-nitrosylation is a ubiquitous post-translational modification, able to influence a variety of biological processes including the homeostatic inhibition of the NF-κB transcriptional activity in cortical neurons exposed to NMDA receptor overstimulation.

2 October 2026 in Science Advances
Verified
Journal Article
Open access
HHHernan Hernandez
Hernan Hernandez
LPLizeth Katherine Pedraza
Lizeth Katherine Pedraza
HSHernando Santamaria-Garcia
Hernando Santamaria-Garcia
SMSebastian Moguilner
Sebastian Moguilner
ALAgustina Legaz
Agustina Legaz
AIAgustin Ibanez
Agustin Ibanez
Biological aging clocks offer estimations of aging and dementia, yet scalability is limited. We introduce a large-scale, cross-national speech clock derived from 2928 individuals across five Latin American countries, spanning healthy controls (HCs), mild cognitive impairment (MCI), Alzheimer’s disease (AD), and non-language/language-dominant frontotemporal dementia (nldFTD/ldFTD). Multimodal acoustic and linguistic features were trained with supervised models to estimate chronological age, generating speech age gaps (SAGs) as cross-sectional markers of deviations from chronological age, with positive values interpreted as relatively older-appearing speech profiles. SAGs differentiated diagnostic groups (HCs < patient groups, with AD < nldFTD < ldFTD). This pattern was associated with clinical/cognitive domains. SAGs correlated with phosphorylated tau (p-Tau217) in AD and social exposome in HCs and AD. Brain clocks (structural/functional/combined) were associated with SAG in AD, nldFTD, and ldFTD. Epigenetic age correlated with SAGs in HCs and AD across Hannum, Retroclock, and OMICmAge, whereas ldFTD associations were limited to Retroclock and OMICmAge. These results indicate that SAGs capture cross-sectional multilevel aging-related variation and may offer a scalable, culturally adaptable, low-cost biomarker candidate for research in underrepresented global settings.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ACAriel Caviedes
Ariel Caviedes
POPaulina Orellana
Paulina Orellana
HHHernan Hernandez
Hernan Hernandez
ASAndrea Slachevsky
Andrea Slachevsky
MBMaría Isabel Behrens
María Isabel Behrens
CDClaudia Duran‐Aniotz
Claudia Duran‐Aniotz
Background: Dementia, encompassing Alzheimer's disease (AD) and frontotemporal dementia (FTD), poses a substantial public health challenge in Latin America. Barriers such as a shortage of healthcare professionals, limited medical accessibility, and underdiagnosis contribute to the complexity. While biomarkers aligned with the ATN framework (Amyloid, Tau, Neurodegeneration) have revolutionized diagnosis, their cost limits adoption in Latin America. Existing research focuses predominantly on North American or European cohorts, leaving a significant gap for the region. Our groundbreaking study aims to investigate, for the first time, ATN‐related proteins in AD, FTD, and control subjects using blood samples from the ReDLat cohort. This research addresses critical gaps in dementia diagnosis specific to Latin America, guided by insights from the ATN framework.Method: We enrolled 500 participants (AD, FTD, and healthy controls‐HC) from Argentina, Chile, Colombia, Mexico, and Peru through the Multi‐Partner Consortium to Expand Dementia Research in Latin America (ReDLat). Plasma samples were collected in EDTA tubes, aliquoted, shipped on dry ice, and stored at ‐80°C following standard methods. We assess the plasma levels of Aβ40, Aβ42, p‐tau181, and NfL across groups (AD, FTD, HC) using Lumipulse G600II from Fujirebio, an advanced automated system which detects proteins via chemiluminescence.Result: Our analysis revealed a significant decrease in the Aβ1‐42/40 ratio between AD and FTD patients compared to HC. Additionally, we observed a significant increase in p‐tau181 levels in both AD and FTD patients relative to HC, with a significant difference between AD and FTD. NfL levels were significantly higher in AD and FTD patients compared to HC.Conclusion: Our findings demonstrate substantial differences in Aβ1‐42/40 ratio, phosphorylated Tau, and NfL levels between AD, FTD, and control subjects. These distinct biomarker profiles hold promise for distinguishing between various forms of dementia and healthy individuals. Importantly, our study addresses the critical gap in dementia research within LA populations, offering valuable insights into the potential impact of regional factors on biomarker dynamics.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
POPaulina Orellana
Paulina Orellana
ACAriel Caviedes
Ariel Caviedes
CGCarolina Gonzalez
Carolina Gonzalez
SSStefanny Salcidua
Stefanny Salcidua
FHFernando Henriquez
Fernando Henriquez
Claudia Duran-AniotzClaudia Duran-Aniotz
Claudia Duran-Aniotz
Background: Timely diagnosis of Alzheimer’s disease (AD) is a critical first step in clinical care treatment. However, the availability of diagnostic tools for these conditions is either unavailable or unaffordable, especially in Latin American and the Caribbean (LAC) countries. In this scenario, microRNAs (miRNA) have recently emerged as promising cost‐effective and noninvasive biomarkers since they can be readily detected in different biofluids such as plasma bound to protein or inside exosomes. Our aim is to identify new blood biomarkers to calculate the risk to develop AD in the early stages using machine learning based on exosomal miRNAs detection and different cognitive domains.Method: miRNAs were extracted from plasma circulating exosomes samples of Subjective Cognitive Complaint subjects belonging to the GERO cohort in two different times (T1 = baseline and T2 = 18 months, n = 50). miRNAs were sequencing to identify the expression levels. Dysregulated miRNAs were analyzed and correlated with neuropsychological evaluations to create machine learning algorithms. miRNAs obtained from algorithms were validated in a new population of subjects at both stages (T1 and T2, n = 50), using qRT‐PCR and correlation analysis with neuropsychological tests.Result: For algorithm development, we classified subjects into stationary and progressive impairment. Algorithms were trained using the sequenced miRNAs, neuropsychological tests and neuroimaging. As possible predictors of progression of cognitive impairment, the best performing algorithm was Random forest using only miRNAs data. In a new group of subjects, three miRNAs selected by the algorithm and four miRNAs obtained from the literature were validated and the ROC curves were constructed. The combination of these miRNAs (algorithm and literature miRNAs), were the best predictor of the progression of cognitive impairment.Conclusion: This study could be used in the initial phases of the diagnostic process of AD because it is minimally invasive, low cost and accessible to a large number of patients in Latin American and the Caribbean (LAC) countries.